120, Huntington Ave

Boston,

MA,

USA,

ZIP: 02116

Phone: 16174554188

Built with the field's thought-leaders from the likes of Pfizer, Biogen, Voyager and Novartis, GTxN is the industry's first and only meeting dedicated to solving your translational drug development challenges enabling you to accelerate the development of your neurological gene therapy candidate.

- Review recent gene therapy clinical successes and failures targeting neurological disorders to identify improvement areas and opportunities to guide your future research
- Discover the latest advances in administration routes and vector engineering to improve delivery success
- Address immunogenicity and the dosage challenges seen with gene therapies to identify the optimal therapeutic window

Join 60+ of your peers at this definitive conference over 3 days, 2 interactive workshops, 6+ hours of dedicated networking time and 18 expert industry speakers.

URLs:
Tickets: https://go.evvnt.com/503662-1?pid=1052
Brochure: https://go.evvnt.com/503662-3?pid=1052

Boris Gorovits, Senior Director, Pfizer, Carl Morris, Chief Scientific Officer, Solid Biosciences, Greg LaRosa, Senior Vice President and Chief Scientific Officer, Rare Disease Research Unit,  Pfizer, Joyce Lo, Scientist II, Biogen, Mark Milton, Global Head, Pharmacokinetic Sciences Ophthalmology Therapeutic Area and Department Lead for Gene Therapies, Novartis, Martin Childers, Chief Medical Officer, AskBio, Natasha Penner, Director, Clinical Pharmacology and Pharmacometrics, Biogen, Robert Bell, Associate Research Fellow, Pfizer, Timothy MacLachlan, Executive Director, Global Head of Biologics Safety Assessment, Novartis, Lamya Shihabuddin, Head of Genetic Neurologic Diseases, Sanofi, Martin Citron, Vice President, Neuroscience Research, UCB, Gabriele Proetzel, Director, Neuroscience External Research,  Takeda, Sander Van Deventer, Executive Vice President, Research and Product Development, uniQure, David Schaffer, Professor of Chemical and Biomolecular Engineering, UC Berkeley and Co-Founder and Acting Chief Scientific Officer, 4D Molecular Therapeutics, Gavin Corcoran, Chief Research and Development Officer,  Axovant, Omar Khwaja, Chief Medical Officer, Voyager Therapeutics, David Theron, Prospective and Opportunities Director, CNS, Servier, Krzysztof Bankiewicz, Professor and Chair, University of California, Klaudia Kuranda, Immunology Leader, Spark Therapeutics